Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Frydman Marom, Anat ^a   Levin, Aviad ^a   Farfara, Dorit ^a   Benromano, Tali ^a   Scherzer Attali, Roni ^a   Peled, Sivan ^a   Vassar, Robert ^b   Segal, Daniel ^a   Gazit, Ehud ^a   Frenkel, Dan ^a   Ovadia, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CINNAMON EXTRACT; OLIGOMER; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLY; IMMUNOPRECIPITATION; IN VIVO STUDY; LOCOMOTION; LONGEVITY; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; OUTCOME ASSESSMENT; PROPHYLAXIS; RECOGNITION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; CINNAMOMUM ZEYLANICUM; DISEASE MODEL; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALIA; CINNAMOMUM VERUM; MUS; MUS MUSCULUS;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CINNAMOMUM ZEYLANICUM; COGNITION DISORDERS; DIPTERA; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; PROTEIN MULTIMERIZATION; TREATMENT OUTCOME;

EID: 79551537131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016564     Document Type: Article

References (43)

1. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362: 329-344.
2. Van Leuven F (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61: 305-312.
3. Gazit E (2004) The role of prefibrillar assemblies in the pathogenesis of amyloid diseases. Drugs Fut 29: 613-619.
4. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abre J, et al. (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A beta oligomerization. FASEB J 18: 1366-1372.
5. Kayed R, Head E, Thompson JI, MeIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300: 486-489.
6. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neuroscience 1: 79-84.
7. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid -β protein assembly in the brain impairs memory. Nature 440: 352-357.
8. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101: 1172-1184.
9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
10. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95: 834-847.
11. Prins ND, Visser PJ, Scheltens P (2010) Can novel therapeutics halt the amyloid cascade? Alzheimers Res Ther 2: 5.
12. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, et al. (2009) Amyloidbeta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12: 1567-1576.
13. Kim W, Kim Y, Min J, Kim DJ, Chang Y, et al. (2006) A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem Biol. pp 461-469.
14. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, et al. (2009) Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl 48: 1981-1986.
15. Frenkel D, Puckett L, Petrovic S, Xia W, Chen G, et al. (2008) A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann Neurol 63: 591-601.
16. Scherzer-Attali R, Pellarin R, Convertino M, Frydman-Marom A, Egoz-Matia N, et al. (2010) Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One 5: e11101.
17. Paiva SAR, Russell RM (1999) Beta-Carotene and Other Carotenoids as Antioxidants. J Am Coll Nutr 18: 426-433.
18. Mee Young H, Navindra PS, Yanjun Z, David H (2008) Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr biochem 19: 448-458.
19. Chauhan NB, Sandoval J (2007) Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice. Phytother Res 21: 629-640.
20. Ono K, Condron MM, Ho L, Wang J, Zhao W, et al. (2008) Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J Biol Chem 283: 32176-32187.
21. Kim DS, Kim JY, Han YS (2007) Alzheimer's disease drug discovery from herbs: neuroprotectivity from beta-amyloid (1-42) insult. J Altern Complement Med 13: 333-340.
22. Dugoua JJ, Seely D, Perri D, Cooley K, Forelli T, et al. (2007) From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. Can J Physiol Pharmacol 85: 837-847.
23. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA (2003) Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 26: 3215-3218.
24. Brahmachari S, Jana A, Pahan K (2009) Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 183: 5917-5927.
25. Ouattara B, Simard RE, Holley RA, Piette GJ, Begin A (1997) Antibacterial activity of selected fatty acids and essential oils against six meat spoilage organisms. Int J Food Microbiol 37: 155-162.
26. Peterson DW, George RC, Scaramozzino F, LaPointe NE, Anderson RA, et al. (2009) Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro. J Alzheimers Dis 17: 585-597.
27. Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, et al. (2004) Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem 52: 65-70.
28. Sevillia G, Kamensky M, Finger A, Ovadia M (2007) Cinnamon Extract Inhibits Avian Influenza H9N2 Both In-Vitro and In-Vivo. Options for the control of Influenza VI Proceedings. pp 467-469.
29. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr., et al. (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270: 7013-7016.
30. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, et al. (1993) Beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A 90: 10836-10840.
31. Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 24: 144-148.
32. Crowther DC, KIinghorn KJ, Miranda E, Page R, Curry JA, et al. (2005) Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a drosophila model of Alzheimer's disease. Neuroscience 132: 123-135.
33. Moloney A, Sattelle DB, Lomas DA, Crowther DC (2009) Alzheimer's disease: insights from Drosophila melanogaster models. Trends Biochem Sci 35: 228-235.
34. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. (2001) The'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4: 887-893.
35. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. (2006) Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation. J Neurosci 26: 10129-10140.
36. Spires TL, Hyman BT (2005) Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2: 423-437.
37. Bevins RA, Besheer J (2006) Object recognition in rats and mice: a one-trial nonmatching-to-sample learning task to study'recognition memory'. Nat Protoc 1: 1306-1311.
38. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, et al. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15: 558-566.
39. Hamaguchi T, Ono K, Yamada M (2010) Curcumin and Alzheimer's Disease. CNS Neurosci Ther ahead of print.
40. Panickar KS, Polansky MM, Anderson RA (2009) Cinnamon polyphenols attenuate cell swelling and mitochondrial dysfunction following oxygen-glucose deprivation in glial cells. Exp Neurol 216: 420-427.
41. Porat Y, Mazor Y, Efrat S, Gazit E (2004) Inhibition of Islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43: 14454-14462.
42. Bastianetto S, Krantic S, Quirion R (2008) Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev Med Chem 8: 429-435.
43. Shoval H, Weiner L, Gazit E, Levy M, Pinchuk I, et al. (2008) Polyphenolinduced dissociation of various amyloid fibrils results in a methionineindependent formation of ROS. Biochim Biophys Acta 1784: 1570-1577.